The US Food and Drug Administration named Dexcom as the first manufacturer selected for its Technology-Enabled Meaningful Patient Outcomes pilot on Tuesday. The programme, known as TEMPO, allows digital health devices to be offered to Med
It is intended to let patients and their clinicians monitor metabolic and nutritional status, receive tailored guidance, and access real-time data and AI insights for behavioural changes.
It’s for “Digital Health Devices.”
Maaaaan. If only I were rich and living in the US. It’s a new frontier of snake oil.
Just get in His Majesty’s good graces and go to town.
It’s a glucose monitor, like diabetics already use, it’s not snake oil.